TITLE:
      Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries
SUMMARY:
      The primary objective is to assess the safety profile of IC51 in a pediatric population from
      regions where JEV is not endemic
ELIGIBILITY CRITERIA:
      Inclusion Criteria:

          -  Male or female healthy children and adolescents aged >=2 months to <18 years at the
             time of first vaccination

          -  Written informed consent by the subject's legal representative(s), according to local
             requirements, and written informed assent of the subject, if applicable

          -  Female subjects: either no childbearing potential or negative pregnancy test. For
             females after menarche willingness to practice a reliable method of contraception.

          -  The subject is planning to travel to an area where JE is endemic after completion of
             the vaccination schedule. Exposure to JE should be avoided until 1 week after the
             second IC51 dose and subjects should return from travel to JE endemic areas before
             the Month 7 visit. The planned travel to JE endemic areas should not interfere with
             the study visits and can take place between Visit 2 + 7 days to Month 7.

        Exclusion Criteria:

          -  Clinical manifestation or history of any Flavivirus disease

          -  Vaccination against JE (except within this protocol), Yellow fever, West Nile virus
             and Dengue at any time prior or during the study

          -  History of immunodeficiency or immunosuppressive therapy

          -  Known HIV, HBV or HCV infection

          -  History of hypersensitivity reactions to other vaccines

          -  Acute febrile infection at each visit during which the subject receives a vaccination

          -  Active or passive immunization within 1 week before and 1 week after each IC51
             vaccination.
